BioinvestGPT

BioinvestGPT ApS · Research use only

NCT03616470 (Uproleselan in Relapsed/​Refractory Acute Myeloid Leukemia): BVCT ex-ante prediction vs. reported outcome

On 16 Feb 2024, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. 2 readouts followed: 6 May 2024, True Negative (TN); 29 Oct 2024, True Negative (TN).

Clinical Trial

NCTID
NCT03616470
Drug Name
Uproleselan (GMI-1271)
Drug MoA
selective E-selectin antagonist
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Relapsed/​Refractory Acute Myeloid Leukemia
Human Patients
388
Sponsor
GlycoMimetics
Phase
Phase 3

Prediction of , index 1441

Prospective Prediction
Prediction Index
1441
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit)
Technical Prediction
partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in OS)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
80 days in advance
Readout Data Interpretation
OS primary endpoint not met.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
256 days in advance
Readout Data Interpretation
uproleselan failed to achieve the EFS primary efficacy endpoint
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase
Phase 3
Status
Terminated
Enrollment
388
Lead sponsor
GlycoMimetics Incorporated
Conditions
Acute Myeloid Leukemia
Interventions
DRUG: Uproleselan; DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2018-10-15
Primary completion
2024-03-31
Completion
2024-03-31
Primary outcomes
  • Overall survival (5 years)

NCT03616470 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials